EUVIMEDEUVIMED entdecken
Crossref

Intrainfusion Drug Monitoring and Algorithm-Based Dose Adjustments for Children With ALL Receiving High-Dose Methotrexate Are Feasible and Safe in Costa Rica, a Low- and Middle-Income Country

Karol Acevedo iD, Gabriela Soto, Mary C Shapiro, Jennifer H Foster iD, Kathia Valverde, Eric S Schafer iD, Judith Margolin

JCO Global Oncology · 2025

DOI: 10.1200/go-24-00450 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2025. Verfasst von Karol Acevedo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Hospital Nacional de Niños, Dr Carlos Sáenz Herrera, Caja Costarricense de Seguro Social, San José, Costa Rica. Hauptthemen laut MEDLINE: Methotrexate, Drug Monitoring, Antimetabolites, Antineoplastic. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Infusions of high-dose methotrexate at 5 g/m 2 over 24 (HDMTX) as a single infusion for pediatric patients with high-risk precursor B-cell ALL are known to lead to superior outcomes. The Hospital Nacional de Niños Dr Carlos Sáenz Herrera, part of the public system Caja Costarricense de Seguro Social in Costa Rica (HNN), has been historically unable to provide this therapy secondary to the required intensive monitoring and cost-prohibitive toxicity support. METHODS We report our experience providing HDMTX at HNN, to our knowledge, for the first time using an algorithm-based individualized HDMTX protocol designed to prevent toxic levels of methotrexate. The protocol checks intrainfusion methotrexate levels at hours 2 and 6 or 8, with adjustments in the infusion downward if levels predict a high/toxic end infusion concentration. RESULTS Fifty-two patients (who received 196 total evaluable infusions between 2017 and 2019) were included. Rate adjustments were required during 51 infusions (24.6%). Significant methotrexate-related toxicities were rare and included acute kidney injury (≥grade 3, 0.5%, n = 1), neurotoxicity (≥grade 3, 1%, n = 2), mucositis (≥grade 3, 4.8%, n = 10), and neutropenia (≥grade 3, 24.6%, n = 51). No ≥grade 4 toxicities occurred. CONCLUSION A real-time, algorithm-based individualized HDMTX infusion is a practical and safe way to administer HDMTX in a low- and middle-income country.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateDrug MonitoringAntimetabolites, AntineoplasticHumansCosta RicaAlgorithmsChildMaleFemaleChild, PreschoolAdolescentInfantInfusions, Intravenous

Substanzen

MethotrexateAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Hematology Department, Hospital Nacional de Niños, Dr Carlos Sáenz Herrera, Caja Costarricense de Seguro Social, San José, Costa Rica.
  • Department of Pediatrics, Baylor College of Medicine, Houston, TX.
  • Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX.

ORCID-Profile: Karol Acevedo, Jennifer H Foster, Eric S Schafer

Zitieren

APA

Acevedo, K., Soto, G., Shapiro, M. C., Foster, J. H., Valverde, K., Schafer, E. S., & Margolin, J. (2025). Intrainfusion Drug Monitoring and Algorithm-Based Dose Adjustments for Children With ALL Receiving High-Dose Methotrexate Are Feasible and Safe in Costa Rica, a Low- and Middle-Income Country. JCO Global Oncology. https://doi.org/10.1200/go-24-00450

Vancouver

Acevedo K, Soto G, Shapiro MC, Foster JH, Valverde K, Schafer ES, et al. Intrainfusion Drug Monitoring and Algorithm-Based Dose Adjustments for Children With ALL Receiving High-Dose Methotrexate Are Feasible and Safe in Costa Rica, a Low- and Middle-Income Country. JCO Global Oncology. 2025. doi:10.1200/go-24-00450

BibTeX
@article{Acevedo2025,
  author = {Acevedo, Karol and Soto, Gabriela and Shapiro, Mary C and Foster, Jennifer H and Valverde, Kathia and Schafer, Eric S and Margolin, Judith},
  title = {Intrainfusion Drug Monitoring and Algorithm-Based Dose Adjustments for Children With ALL Receiving High-Dose Methotrexate Are Feasible and Safe in Costa Rica, a Low- and Middle-Income Country},
  journal = {JCO Global Oncology},
  year = {2025},
  doi = {10.1200/go-24-00450}
}
Kostenlos starten →